Naslov
Risk factors for the occurrence and irreversibility of cardiotoxicity caused by trastuzumab therapy

Autori
Gabrić, Ivo Darko ; Vazdar, Ljubica ; Pintarić, Hrvoje ; Planinc, Danijel ; Štefanović, Mario ; Trbušić, Matias ; Vinter, Ozren ; Jazvić, Marija ; Soldić, Željko ; Šeparović, Robert

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the Heart Failure 2015 and the 2nd World Congress on Acute Heart Failure. U: European Journal of Heart Failure 17(S1) / - , 2015, 26-26

Skup
2nd World Congress on Acute Heart Failure

Mjesto i datum
Sevilla, Španjolska, 23.05.2015. - 26.05.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
cardiotoxicity ; trastuzumab ; breast cancer

Sažetak
Cardiotoxicity is the most important side effect of trastuzumab, humanized monoclonal antibody to the HER2 protein, in use for immunotherapy of breast cancer. It is mainly manifested as a reduction in left ventricular contractility without myocardial necrosis and the process is therefore mostly reversible. However, sometimes the disease can progress to irreversible dilated cardiomyopathy. So far, many risk factors explaining cardiotoxicity have been identified, but it is still unclear how to assess individual risk. Also, there are no defined factors that can predict irreversibility of the disease. Pts with D/D ACE genotype, tumor of the left breast and positive family history of cardiovascular disease have a higher risk of developing cardiotoxicity with trastuzumab therapy and should be treated as high risk pts. Trastuzumab induced cardiotoxicity ismore likely to be irreversible in pts with a more extensive decrease of the LVEF and a higher serum NT-proBNP level. The time between prior chemotherapy and administration of trastuzumab shorter than 30 days ismore often associated with irreversible cardiac impairment.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA